Prantera 2006.

Methods	Randomized placebo controlled trial. Investigators and patients were blinded Intention to treat Twelve week trial
Participants	Patients aged 18‐70 with mild to moderate CD (CDAI 200‐400) (N = 83)
Interventions	Randomized to receive oral rifaximin 800 mg daily (n = 25) and oral placebo, oral rifaximin 800 mg BID (n = 29) or oral placebo BID (n = 29). Other immunosuppressant’s kept at same dose of during study period
Outcomes	Primary outcome: Clinical remission defined by CDAI ≤ 150 Secondary outcomes: Reduction of CDAI ≥ 70 points from baseline, treatment failure and changes in quality of life (Inflammatory Bowel Disease questionnaire)
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding of participants and investigators
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Investigators blinded to participant assignment. CDAI and the Inflammatory Bowel Disease Questionnaire (IBDQ) scores were calculated by blinded investigators
Incomplete outcome data (attrition bias) All outcomes	Low risk	Discontinuation and reasons for withdrawal were fairly even between each group. (rifaximin 800 mg daily and placebo 8/25, rifaximin 800 mg BID 12/29 or placebo BID 13/29)
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	No other apparent sources of bias